Roller coaster for Valneva’s inactivated Covid-19 vaccine

Monday, 16 May 2022 11:19

Foto: (c) Towfiqu Barbhuiya / unsplash.comValneva SE announced that the United Arab Emirates (UAE) granted emergency use authorization for its inactivated, adjuvanted COVID-19 vaccine, VLA2001.

With the approval of the United Arab Emirates (UAE), this is the second approval in the Gulf countries. But at the same time Valneva SE has received a notice from the European Commission (“EC”) of intent to terminate the advance purchase agreement (“APA”) for VLA2001.

The APA provides the EC with a right to terminate the APA if VLA2001 had not received a marketing authorization from the European Medicines Agency (“EMA”) by April 30, 2022. Based on the terms of the APA, Valneva has 30 days from May 13, 2022 to obtain a marketing authorization or propose an acceptable remediation plan.

The Company will work with the EC and the participating EC member states to agree to a remediation plan and to make VLA2001 available to those member states who still wish to receive it.

Valneva SE has started a dialogue with member states who are interested in the inactivated approach. Valneva continues to believe that its vaccine candidate VLA2001 can make an important contribution to the fight against COVID-19 and complement existing vaccines with an inactivated, whole virus approach”.

The Company announced on April 25, 2022 that it received a further List of Questions (“LoQ”) from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA. Valneva submitted its responses on May 2, 2022 and believes that they adequately address the remaining questions. If the CHMP accepts Valneva’s responses, the Company would expect to receive a positive CHMP opinion at the latest in June 2022.

VLA2001 so far received a Conditional Marketing Authorization from the Medicines and Healthcare products Regulatory Agency in the United Kingdom on April 14, 2022 and Emergency Use Authorizations from the Ministry of Health & Prevention of the United Arab Emirates and from the National Health Regulatory Authority in Bahrain on May 13, 2022 and on February 28, 2022, respectively.

If the EC ultimately terminates the APA, Valneva will not be required to return the down payments received since Valneva has committed the full amount of those down payments and the APA does not require reimbursement of such payments under these circumstances.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. VLA2001’s manufacturing process, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 to 8 degrees Celsius).

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to possible regulatory approval of VLA2001. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of future results. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual property protection and the impact of the COVID-19 pandemic. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

(GZ)
Quelle: Valneva
Foto: (c) Towfiqu Barbhuiya / unsplash.com

Bei Rückfragen zum Artikel wenden Sie sich
bitte direkt an die im Artikel angegebene Kontaktadresse.

.fusion-widget-area-1 {padding:0px 0px 0px 0px;}.fusion-widget-area-1 .widget h4 {color:#4c5166;}.fusion-widget-area-1 .widget .heading h4 {color:#4c5166;}.fusion-widget-area-1 .widget h4 {font-size:24px;}.fusion-widget-area-1 .widget .heading h4 {font-size:24px;}
jobbörse für Naturwissenschaftler

Der Beitrag Roller coaster for Valneva’s inactivated Covid-19 vaccine erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen.

Read more https://life-science.eu/roller-coaster-for-valnevas-inactivated-covid-19-vaccine/

Published in life-science
  • FEMS - Get Involved bulletin – June 2022
    The FEMS Get involved bulletin is out! Read the June issue with microbiology research, events and calls. In this bulletin:l FEMS Conference #FEMSmicroBlog Opportunities Board FEMS Journal News   Deadlines: Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a very wide international network and is a member of several relevant scientific societies like FEMS. ÖGMBT…
    24.06.2022,
  • Submission deadline for the Life Science Austria Awards extended until June 15, 2022
    The submission deadline for the "Life Science Awards Austria 22" has been extended until June 15, 2022.
    31.05.2022,
  • FEMS - Get Involved bulletin – May 2022
    The FEMS Get involved bulletin is out! Read the May issue with microbiology research, events and calls. In this bulletin: FEMS Summer School FEMS Conference Story writing competition #FEMSmicroBlog FEMS Journal News   Deadlines: FEMS Summer School: 1 June 2022 Meeting Organizer Grants: 1 June 2022 Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a…
    31.05.2022,
  • Short Story Writing Competition – How Will Microbiology Change Our Future?
    Do you have ideas for crazy stories about how microbiology could change our future? Then join the competition. The #FEMSmicroBlog is opening a short story writing competition to showcase how microbiology touches our lives. Deadline for submission is 30 June 2022 For more information please look here:   https://fems-microbiology.org/short-story-writing-competition-how-will-microbiology-change-our-future/    
    30.05.2022,
  • FEMS Affiliates Letter - April 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of April 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    06.05.2022,
  • FEMS - Get Involved bulletin – April 2022
    The FEMS Get involved bulletin is out! Read the April issue with microbiology research, events and calls. In this bulletin: #FEMSmicroBlog, Podcast & Opportunities Board FEMS Journal News   Deadlines: Meeting Organizer Grants: 1 June 2022 Research and Training Grants: 1 July 2022 Industry Placement Grants: 1 August 2022 Meeting Attendance Grants: 1 September 2022   The ÖGMBT has a very wide international network and is a member of several…
    29.04.2022,
  • FEMS Affiliates Letter - March 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of March  2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    04.04.2022,
  • FEMS Affiliates Letter - February 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of February 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    01.03.2022,
  • FEMS - Get Involved bulletin – February 2022
    The FEMS Get involved bulletin is out! Read the February issue with microbiology research, events and calls. In this bulletin: FEMS Volunteer teams #FEMSmicroBlog, Podcast & Opportunities Board FEMS Journal News FEMS Conference - Late Abstracts Deadlines: Meeting Attendance Grant: 1 March 2022 Meeting Organizer Grant: 1 June 2022   The ÖGMBT has a very wide international network and is a member of several relevant scientific societies like FEMS. ÖGMBT…
    24.02.2022,
  • FEMS Affiliates Letter - January 2022
    As member of the ÖGMBT you are automatically also member of the Federation of European Microbiology Societies (FEMS). The FEMS Affiliates Letter of January 2022 has the following content:   1. Microbiology News and Events 2. The FEMS Journals 3. Policy Corner 4. Grants Corner 5. Opportunities 6. Extras  
    31.01.2022,
  • Bioblast 2022: BEC Inaugural Conference
    Oroboros Instruments richtet vom 29. - 30. Juni 2022 die Bioblast 2022: BEC Inaugural Conference im Congress Innsbruck aus. Dabei treffen sich internationale WissenschafterInnen, tätig in den Bereichen der mitochondrialen Physiologie und Photosynthese (besonders von Algen), um sich über die neuesten wissenschaftlichen Erkenntnisse auszutauschen. Die Kongressbeiträge werden im open-access und living communications Journal Bioenergetics Communications (BEC) veröffentlicht und wir sind für Beiträge offen: » Bioenergetics Communications Des Weiteren möchte Oroboros den Mitgliedern der ÖGMBT die Möglichkeit geben,…
    10.05.2022,
  • Erklärvideo zu Totimpfstoffen gegen COVID-19
    Das neue Erklärvideo von Open Science "SARS-CoV-2: Totimpfstoffe" ist fertig - rechtzeitig zum Start der Impfung mit dem Proteinimpfstoff von Novavax! Das Video, das in Kooperation mit dem Doktoratskolleg RNA-Biologie und der FH Campus Wien entstanden ist, erklärt, wie inaktivierte Ganzvirus- und Proteinimpfstoffe gegen COVID-19 hergestellt werden, was sie beinhalten und wie sie wirken.    
    02.03.2022,
  • Labbuddy - Training lab teaching
    We developed a training on teaching in the lab, in which we will provide teachers with tips and tricks that will help them inspire student learning in the lab. Laboratory course teaching fundamentals Teaching seems easy…….. ………until the moment you need to teach! Teaching is a true profession, but everyone can learn how to teach. Do you need to teach because of your Ph.D. study, or are you a teacher…
    27.01.2022,
    by
  • Open Call for Applications: 4 Fellowships 4 Entrepreneurs 2022
    Do you have an entrepreneurial idea that you want to develop under the guidance of experts? Are you ready to sound out your entrepreneurial spirit? Then the LBG Career Center might have the right program for you! Within the 4 Fellowships 4 Entrepreneurs program, you will build foundational knowledge about entrepreneurship, receive support on your journey to launching your ideas, and start on the path to becoming an entrepreneur.Throughout 9 months,…
    18.01.2022,
    by
  • FEBS Junior Sections Talk Series 2022
    FEBS Junior Sections Talk Series 2022 We have planned a series of monthly talks for 2022, alternating academic and career topics, each organized by a Junior Section from a different country. 13th January. Academic. Organized by Junior-GBM (the Junior Section of the German Society, GBM). A talk by Dr Andreas Schlundt, from Goethe University Frankfurt, on “The roles of sequence, structure and dynamics for specific RNA-recognition by proteins". Watch the recorded…
    18.01.2022,
    by
  • BCF Career events
    Activate your career dreams in Life Sciences with BCF Career Are you a newly graduate looking for your first job, a (young) professional looking for the next step in your career or simply interested in enhancing your career? Join our (online) BCF Career Events:   17 February 2022 - BCF Career Event Benelux - Online edition 19 May 2022 - BCF Career Event Netherlands - Jaarbeurs Utrecht 16 November 2022…
    29.12.2021,
    by
  • Chemiereport 8/21
    Chemiereport 8/12- the 8th edition of Chemiereport is out featuring news from life science world in Austria and most importantly covering article under the title  ”ÖGMBT presents career opportunities in the Life Sciences”.  In the article ÖGMBT interim manager Andrea Bauer speaks on all the ways ÖGMBT and ÖGMBT-YLSA explore possibilities for young life scientists in the field. More so by organizing variety of career events, presenting job profiles on…
    29.12.2021,
    by
  • YSF (Young Scientists Forum) 2022 Portugal
    2022 IUBMB–FEBS–PABMB Young Scientists’ Forum (YSF 2022) will be held just ahead of – and in conjunction with – the joint 25th IUBMB, 46th FEBS and 15th PABMB Congress. The exciting YSF 2022 will take place at Vimeiro, located on the Portuguese coast alongside a peaceful beach with a fantastic view of the endless Atlantic Ocean. The YSF 2022 meeting will bring together around 120 selected young researchers in biochemistry…
    24.11.2021,
    by
  • IUBMB grants
    IUBMB grants- There is variety of travel and fellowship grants for young researchers from International Union of Biochemistry and Molecular Biology with upcoming deadlines.  Check it out here.
    04.11.2021,
    by
  • FEBS-IUBMB-ENABLE 2022 Symposium – a PhD and Postdoc meeting
    FEBS-IUBMB-ENABLE are now looking for an academic institution (either a university or a research institution) in Europe with a strong research background in molecular life sciences and an active PhD community to host the November 2022 conference. This event will be organized by a committee of young researchers belonging to the four ENABLE institutions (core institutions, as listed above) plus the selected host institution (associated institution). It will be organized…
    25.08.2021,
    by
  • Unitleitung Compliance (w/m/d)
    Unitleitung Compliance (w/m/d) Boehringer Ingelheim RCVDer Beitrag Unitleitung Compliance (w/m/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    24.06.2022,
  • Analytiker – Endotoxinlabor/Microbiology (w/m/d)
    Analytiker – Endotoxinlabor/Microbiology (w/m/d) Boehringer Ingelheim RCVDer Beitrag Analytiker – Endotoxinlabor/Microbiology (w/m/d) erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    24.06.2022,
  • Corporate Trainee Production – MSAT Management (m/f/d
    Corporate Trainee Production – MSAT Management (m/f/d Octapharma Pharmazeutika Produktionsges.m.b.H.Der Beitrag Corporate Trainee Production – MSAT Management (m/f/d erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    24.06.2022,
  • Gefährliche Wildbäche können das Bergerlebnis trüben
    Auch idyllische kleine Gebirgsbäche können zu gefährlich, reißenden Wildbächen anwachsen, die große Mengen an Sedimenten mit sich führen. Der Klimawandel verschärft das Risiko für Hochwasser und Vermurungen. Spätestens seit den Ereignissen im Ahrtal 2021 wissen wir, dass extreme Regengüsse und Überschwemmungen auch in den gemäßigten Klimazonen Euro...
    24.06.2022,
  • EMA empfiehlt Valneva’s inaktivierten COVID-19 Impfstoff.
    Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) hat die Marktzulassung für Valnevas inaktivierten COVID-19-Ganzvirusimpfstoffkandidaten VLA2001 zur Verwendung als Erstimpfung bei Menschen im Alter von 18 bis 50 Jahren in Europa empfohlen.Die Europäische Kommission wird die CHMP-Empfehlung prüfen und eine E...
    23.06.2022,
  • In der Ruhe liegt die Kraft
    Das stundenlange meditative Beten, kombiniert mit dem gleichmäßigen Trott des Gehens, hat die Köpfe der Pilger von belastenden Gedanken befreit und ihren Geist wieder für Neues, für Visionen und Inspirationen geöffnet. Sie können NOISIV sehen.Seite 105Am Beginn der Geschichte ist NOISIV den Bewohnern des Dorfes L’larebü als deren Vision...
    22.06.2022,
  • Globale Biotreibstoffproduktion könnte effizienter genutzt werden
    Würde ein kleiner Teil der Anbaufläche von Zuckerrohr, der zur Ethanolgewinnung geerntet wird, für eine ergänzende Anlage in Kombination von Photovoltaik- und Windkraft verwendet werden, könnte die Ethanolproduktion um 43 Prozent gesteigert werden.Brasilien ist weltweit der zweitgrößte Produzent von Biotreibstoffen hinter den USA. Ohne auch nur e...
    22.06.2022,
  • Österreichischer Nachhaltigkeitspreis 2022 vergeben
    Universitäten und Fachhochschulen sind Ausbildungsstätten für künftige Entscheidungsträger/-innen und Zentren für Innovation. Seit 2008 wird der Sustainability Award als österreichweiter Wettbewerb für Universitäten durchgeführt, und soll dazu motivieren, das Leitbild einer nachhaltigen Entwicklung in die eigenen Institutionen und Prozesse zu...
    20.06.2022,
  • Ein Wirkstoff – zwei unterschiedliche Reaktionen
    Graphische Aufbereitung von kultivierten Zellen, die aus der Lunge isoliert wurdenDie Medizinische Universität Graz erforscht gemeinsam mit dem Ludwig Boltzmann Institute für Lungengefäßforschung einen neuen Behandlungsansatz eines bereits bekannten Wirkstoffes gegen Lungenfibrose. Lungenfibrose ist eine schwerwiegende Erkrankung, die dramatische...
    20.06.2022,
  • Trainee Corporate Operational Excellence Data Expert (m/f/d
    Trainee Corporate Operational Excellence Data Expert (m/f/d Octapharma Pharmazeutika Produktionsges.m.b.H.Der Beitrag Trainee Corporate Operational Excellence Data Expert (m/f/d erschien zuerst auf Jobbörse und Netzwerk für Naturwissenschaftler /-innen....
    17.06.2022,